Healthcare Industry News: benign prostatic hyperplasia
News Release - June 26, 2007
Urologix Receives CE Mark for CoolMax(TM) Microwave CatheterMINNEAPOLIS--(HSMN NewsFeed)--Urologix®, Inc. (NASDAQ:ULGX ), today announced that the CoolMax(TM) Microwave Catheter is CE Marked. This new catheter is expected to allow doctors to more comfortably treat men who suffer from the symptoms of BPH, a condition that affects 23 million men.
The CoolMax microwave catheter builds upon Urologix' current product portfolio and leverages its existing technology platform. This catheter is specially designed with Urologix' patented gamma matched dipole antenna design and features the addition of an enlarged cooling balloon. This next generation catheter is part of an ongoing program intended to blend patient comfort with durability. Next, Urologix plans to enter into discussions with the FDA to seek US approval for the device.
"I am pleased with the progress in the development of this catheter and look forward to the future introduction of this product to the US market," commented Fred B. Parks, Urologix Chairman and Chief Executive Officer. "This release signifies our belief that the CoolMax catheter will meet our expectations of improved comfort over our current offering while maintaining the high level of durable outcomes our customers have come to expect from using our products."
In addition to the CoolMax, Urologix offers the Targis® and Cooled ThermoCath® family of catheters along with the Targis® and CoolWave(TM) Control Units. The CoolMax microwave catheter is currently not for sale in the United States.
Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH), a condition that affects more than 23 million men worldwide. Urologix' products include the CoolWave, Targis and Prostatron® control units and the Cooled ThermoCath, Targis and Prostaprobe® catheter families. All of Urologix' products utilize Cooled ThermoTherapy(TM) - targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort - and provide safe, effective, lasting relief of the symptoms of BPH.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include, for example, statements relating to the Company's plans to obtain FDA approval and introduce CoolMax to the US market, and other statements that use such words as "may," "will," "expect," "believe" and "plan."
Actual results may vary significantly from those anticipated in these forward-looking statements due to risks and uncertainties that are detailed from time to time in Urologix' filings with the Securities and Exchange Commission, including its most recently filed Annual Report on Form 10-K for the year ended June 30, 2006.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.